Verma, Neha
Blackford, Amanda L.
Thorner, Elissa
Lehman, Jennifer
Snyder, Claire
Stearns, Vered
Smith, Karen Lisa http://orcid.org/0000-0002-6687-0119
Clinical trials referenced in this document:
Documents that mention this clinical trial
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer
https://doi.org/10.1007/s10549-022-06750-w
Funding for this research was provided by:
Susan G. Komen
NIH (P30 CA006973)
Article History
Received: 2 June 2022
Accepted: 17 September 2022
First Online: 5 October 2022
Declarations
:
: Karen Lisa Smith has received research support (to institution) from Pfizer. Karen Lisa Smith’s spouse has stock ownership in ABT Labs and Abbvie. Vered Stearns has received research grants (to institution) from Abbvie, Biocept, Pfizer, Puma Biotechnology, and Novartis. Vered Stearns has been on an advisory board for Novartis (10/25/21). Vered Stearns is a Data Safety Monitoring Board member for Immunomedics, Inc. and for AstraZeneca. Vered Stearns has received non-financial support from Foundation Medicine for Study Assays. Claire Snyder has research funding (to institution) from Pfizer and Genentech and has received personal consulting fees from Janssen via Health Outcomes Solutions. Elissa Thorner has received research support (to institution) from Pfizer. The following authors declare that they have no conflicts of interest related to the work presented in this manuscript: Neha Verma, Amanda Blackford, and Jennifer Lehman.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. We obtained approval from the Johns Hopkins (JH) Institutional Review Board (IRB) to conduct this prospective study. All participants signed written informed consent.